RxDoctor Payments DataLook up a doctor →

Stacey Epps, MD

Neurology · Chester, VANPI 1154391571

Payments from drug & device makers

$108,865in general payments, 2019–2025

Across 1,268 payments — averaging $85.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$28K
  • Eisai Inc.$23K
  • Lilly USA, LLC$21K
  • Sanofi$15K
  • UCB, Inc.$3K
  • Livanova USA, Inc.$2K
  • plus $17K from 54 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Teva Pharmaceuticals USA, Inc.62$27,799
Eisai Inc.61$22,660
Lilly USA, LLC45$20,929
Sanofi36$15,418
UCB, Inc.164$2,954
Livanova USA, Inc.34$2,299
Medtronic(2 entities)9$1,453
AbbVie(2 entities)155$1,406
Biogen89$1,359
Novartis108$1,311
SK Life Science, Inc.28$1,110
AstraZeneca(2 entities)26$810
Amgen(2 entities)37$716
EMD Serono, Inc.32$661
Lundbeck LLC24$588
Genentech USA, Inc.34$573
E.r. Squibb & Sons, L.L.C.5$517
Sunovion Pharmaceuticals Inc.30$438
Neurelis, Inc.20$429
Bristol Myers Squibb31$409
Greenwich Biosciences, Inc.30$400
Biohaven Pharmaceutical Holding Company Ltd.14$386
Kyowa Kirin, Inc.16$386
Acorda Therapeutics, Inc17$337
Boston Scientific4$325
Biohaven Pharmaceuticals, Inc.15$304
Amneal Pharmaceuticals LLC19$283
Adamas Pharmaceuticals, Inc.9$216
ANI Pharmaceuticals, Inc.5$202
Grifols USA, LLC9$178
Pfizer8$147
Argenx US, Inc.3$132
Jazz Pharmaceuticals Inc.6$126
Assertio Therapeutics, Inc.11$124
Supernus Pharmaceuticals, Inc.9$121
TG Therapeutics, Inc.2$107
Johnson & Johnson(2 entities)4$105
Mallinckrodt Hospital Products Inc.4$103
Neurocrine Biosciences, Inc.6$103
Penumbra, Inc.1$97
Banner Life Sciences, LLC4$84
Sumitomo Pharma America, Inc.4$81
Insightec,inc1$70
CSL Behring4$69
MDD US Operations, LLC4$67
Avanir Pharmaceuticals, Inc.5$61
Catalyst Pharmaceuticals, Inc.3$50
Mallinckrodt Enterprises LLC2$40
Otsuka America Pharmaceutical, Inc.1$38
Avion Pharmaceuticals2$31
GE HealthCare2$29
Upsher-smith Laboratories LLC1$24
Microtransponder, Inc.1$24
Acadia Pharmaceuticals Inc1$23
Alnylam Pharmaceuticals Inc.1$18
C2n Diagnostics, LLC1$16
Takeda Pharmaceuticals U.S.A., Inc.1$16
Collegium Pharmaceutical, Inc.1$15
Impel Pharmaceuticals Inc.1$15
Corium, LLC1$14

How this compares

$108,865 in reported general payments places this provider in the 85th percentile of 474 neurology providers in Virginia.

See all neurology providers in Virginia

Medicare billing

Part B allowed, 2024
$327,292
Medicare patients
992
Services billed
2,548

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other neurology in Chester

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →